New combo therapy aims to tackle advanced liver cancer
NCT ID NCT07587034
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial is testing a new way to treat intermediate and advanced liver cancer. It combines two liver-directed procedures (HAIC and TACE) with two drugs (apatinib and camrelizumab) to see if this approach works better than other combinations. The study will involve 315 adults with liver cancer who cannot have surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
apatinib and camrelizumab
What this could lead to
If successful, this could lead to a more effective treatment strategy for people with intermediate to advanced liver cancer, potentially extending life and controlling tumor growth.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so results may not apply to everyone. The combination therapy also carries risks of side effects from the drugs and procedures.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.